Midbrain raphe hypoechogenicity in migraineurs: An indicator for the use of analgesics but not triptans

Abstract

Introduction

The involvement of the serotonergic system of the brainstem raphe in the pathogenesis of migraine is discussed. Here we studied brainstem alterations in migraineurs using transcranial sonography and examined their relation to clinical features and self-medication.

Methods

We investigated 51 migraineurs (11 men, 40 women, mean age 29.7 ± 11.9 years) and 32 healthy individuals without history of headache or depressive disorder (eight men, 24 women, mean age 34.4 ± 13.0 years). Transcranial sonography was performed in an investigator-blinded fashion. Midbrain raphe echogenicity was quantified using digitized analysis. Migraine characteristics and the use of analgesics were evaluated by applying validated questionnaires. Eight migraineurs underwent neurophysiologic evaluation of contingent stimulus-related cortical potentials.

Results

Echo-reduced midbrain raphe was detected in 27 (53%) migraineurs, but only six (19%) control subjects (odds ratio = 4.87, p = 0.002). Lower raphe echogenicity correlated with both higher amplitude of terminal contingent negative variation (Spearman test, r = 0.76, p = 0.028) and higher use of analgesic drugs (r = −0.45, p = 0.011), but not with use of triptans or with migraine frequency or severity (all p > 0.2). Compared to migraineurs without aura, migraineurs with aura had enlarged third ventricles (t-test, p = 0.014), while the lateral ventricle widths did not differ (p = 0.62).

Conclusions

Midbrain raphe alteration is frequent in migraineurs and relates to self-medication behavior. This alteration may reflect the dysfunction of serotonergic raphe nuclei.

Keywords

Migraine transcranial ultrasound serotonin brainstem raphe analgesics triptans

Introduction

Migraine is the most frequent neurological disorders in the adult population worldwide, affecting up to 12% of the general population (1). The current concepts of this disorder focus on a dysfunction of the descending pain-inhibitory system of the brainstem, leading to hyperexcitability in nociceptive areas (2). In particular, the serotonergic system emerging from the brainstem raphe nucleus has been implicated in migraine pathophysiology, and it has been suggested that a low serotonin state facilitates activation of the trigeminovascular nociceptive pathway, as induced by cortical spreading depression (CSD) (1). Abnormal cortical information processing of sensory stimuli has been proposed as a predisposing factor for migraine via CSD (3,4). In neuroimaging studies a number of morphologic, functional and metabolic alterations of brainstem structures can be linked to migraine, some of them showing a correlation to the duration of the disorder or its severity (5,6). In addition, iron accumulation in the basal ganglia was reported in episodic migraineurs, especially those with higher attack frequency and longer disease duration (7). However, it remains unclear whether these alterations of deep brain structures are caused by the disorder or cause it, and how the different aspects of the pathophysiology influence each other.

Transcranial sonography (TCS) has proved to be reliable in detecting alterations of the midbrain raphe (MBR), substantia nigra and basal ganglia in distinct neurodegenerative disorders, and can sensitively visualize trace metal accumulation (8). For example, TCS studies have consistently demonstrated increased echogenicity (‘hyperechogenicity’) of the substantia nigra in Parkinson’s disease, and of the lenticular nucleus in idiopathic dystonia, but this has not been validated against another imaging measure (8). In depressive disorders TCS has revealed reduced echogenicity (‘hypoechogenicity’) of the MBR, which has been linked to the rarefaction of crossing fiber tracts at the raphe in post-mortem studies, and to alteration of the central serotonergic system (8 –10). The discovery of MBR hypoechogenicity in depressive states has been replicated by numerous independent studies (11). Here, we tested the hypothesis that hypoechogenic alteration of the MBR is frequent in migraineurs. In addition, we wanted to assess whether changes of deep brain structures relate to clinical and neurophysiologic characteristics of migraine, and to the use of analgesic medication.

Methods

Participants

Of the 51 migraineurs (11 men, 40 women, mean age 29.7 ± 11.9 years) who participated in this cross-sectional study, 42 were recruited between April 2014 and February 2015 through an announcement sent via email to all students at the University of Rostock. The remaining nine were patients at the Department of Medical Psychology and Sociology, being trained in cognitive-behavioral pain management. The diagnosis of migraine, according to the International Classification of Headache Disorders (ICHD) diagnostic criteria, had to be confirmed by an expert experienced in the diagnosis and treatment of headache disorders (12). The exclusion criteria were (i) a history of neurological disorder other than the primary headache, (ii) a history of severe head trauma, and (iii) a history of depressive disorder involving medical consultation or treatment. For comparison, 32 healthy control subjects (students and hospital staff members) were included in this study (eight men, 24 women, mean age 34.4 ± 13.0 years), all without a history of episodic or chronic headache, or psychiatric disorders. For each participant the clinical and TCS assessments took place on the same day. The study was approved and registered by the ethics committee at Rostock University (identifier: A-2014-0167), and written informed consent was obtained from each study participant.

Clinical investigations

A validated questionnaire that assessed the pain frequency (recurrent versus permanent), aura symptoms, triggering factors and headache symptoms (13) was used to assign the migraine and tension-type headache diagnoses and record the features of the individual disorder, as well as current medication or self-medication. The data on the history and symptoms of headache were assessed by experts experienced in the diagnosis and treatment of headache disorders. To evaluate allodynia, the migraineurs were asked to rate their agreement with the phrase ‘Combing my hair hurts’ on a scale from 1 to 5. The migraine impact was assessed using the Migraine Disability Assessment Score (14). This scores the days with headache in the past three months, and the severity of the pain, on a visual analogue scale from 1 to 10. All the migraineurs completed the Beck Depression Inventory (BDI) (15).

Transcranial sonography

TCS was performed through the preauricular acoustic bone window using a diagnostic 2.5 MHz phased-array ultrasound system (Acuson Antares, Siemens, Erlangen, Germany) (8,10). The system settings were applied as follows: penetration depth 16 cm, dynamic range 50 dB, post-processing preset G. Migraineurs and control subjects were assessed on TCS in random order by an examiner with 15 years’ experience in TCS (UW), who was blinded to the diagnostic and clinical data. The echogenicity of the MBR was rated visually on a semiquantitative scale ranging from grade 1 to grade 3. Typically, the MBR presents as a clearly visible median line that is highly echogenic compared to the adjacent tissue (grade 3). It can also produce a less intense echo than usual, or the line can be interrupted (grade 2). Sometimes the raphe structures are not identifiable at all despite the clear visibility of red nuclei and basal cisterns (grade 1) (10). Grades 2 and 1 are considered to be abnormal (hypoechogenic). Further brain structures were studied in an exploratory fashion, directed according to the standard TCS protocol applied in neurodegenerative disorders (8). For assessment of the substantia nigra, the echogenic size was calculated automatically according to manually encircled boundaries in an axial scan plane (8). The greater value of the two (bilateral) echogenic sizes was used for further analysis. For the ultrasound system used here, substantia nigra echogenic sizes of <0.24 cm² are considered normal, and sizes >0.24 cm² (upper 25% percentile in a normal population) are considered hyperechogenic. The echogenicity of the red nuclei, lenticular nuclei and heads of caudate were rated as described earlier (8). The widths of the third ventricle and the frontal horns were measured at a standardized axial scanning plane. In addition, an off-line digitized analysis of the anonymized TCS images was performed by a second reader (AR) in order to obtain investigator-independent echo intensity values for MBR, using previously validated MATLAB-based software (16).

Neurophysiologic investigation

Eight migraineurs (one man, seven women, mean age 40.2 ± 19.2 years) underwent assessment of contingent negative variation (CNV), a slow cortical potential recorded between two contingent stimuli (3,4). The demographic and clinical data for these subjects did not differ from the data for the other migraineurs (all p > 0.1). To analyze the CNV, the electroencephalogram was recorded over Cz with linked mastoids as a reference with an electrode resistance of approximately 6 kOhm. The electroencephalogram (bandpass: 0.03–35 Hz) was digitized with a sampling rate of 100 Hz for each channel. All the participants were seated with their eyes open in an armchair located in an electrically shielded, sound-proof room. The auditory warning (S1) and imperative stimulus (S2) were produced by a loudspeaker located behind the subject with an intensity of 75 dB. The interval between S1 and S2 was 3 s. The CNV recording consisted of 32 trials in which the subjects had to react to the imperative stimulus (GO response). To keep the subjects in a vigilant state, eight trials were randomly presented where no reaction was expected (NO-GO response). S1 for the GO response was a 1000 Hz tone which lasted 100 ms. S1 for the NO-GO response was a 200 Hz tone. S2 (f = 2500 Hz) lasted a maximum of 1500 ms and was deactivated by pressing a key. The length of each CNV recording was 6 s, with a randomized interval of 6–10 s between trials. Recordings started 1 s before S1 and ended 2 s following the onset of S2. NO-GO trials were not analyzed. In addition, we recorded a vertical electrooculogram; CNV recordings containing eye blinks or artifacts were discarded. Due to the habituation processes during rejected intervals, a protocol listed the number of rejected trials for each session. The number did not exceed a maximum of two. The periods between the recording onset and S1 were used as the baseline for each trial. The CNV session was finished after 40 artifact-free trials (32 GO, eight NO-GO trials). The 32 GO trials of each CNV session were grand averaged. The overall CNV (oCNV) was the grand-averaged mean amplitude between the onsets of S1 und S2. The initial component (iCNV) was defined as the average amplitude in a window of 200 ms around the maximal amplitude of the expectancy wave between 550–750 ms after S1 (3). The terminal CNV (tCNV) was the average amplitude during the 200 ms preceding S2. The postimperative negative variation (PINV) was the average amplitude of CNV between 500 and 2000 ms following S2. To exclude the effects of the migraine attack on the CNV amplitudes and habituation, we controlled the occurrence of an attack and omitted recordings within three days before or after an attack (4).

Statistical analyses

For the correlation of categorical data, Spearman’s non-parametric rank correlation was used. For the comparison of categorical variables, the chi-square test was used; for the comparison of non-normally distributed data, the Mann-Whitney U test was used; and for the comparison of means, the t-test for independent samples was used. Since the TCS findings were compared with five clinical domains (age, migraine duration, migraine severity, depression severity and use of analgesics), a Bonferroni correction for multiple correlations was employed by dividing a p value < 0.05 by 5; thus a value of p < 0.01 was taken here to be significant for group comparisons. The analyses were performed using SPSS 20 (IBM Corp., Armonk, New York, USA).

Results

Clinical findings

All 51 migraineurs met the ICHD diagnostic criteria for episodic (n = 49) or chronic (n = 2) migraine (11). Twenty-seven migraineurs also met the diagnostic criteria for tension-type headache (co-morbid to their migraine). Thirty-seven migraineurs frequently experienced aura symptoms prior to the headache. The most frequent medications for headache episodes in our cohort were over-the-counter non-opioid analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) like paracetamol and ibuprofen (n = 31 (61%), used on average 4.6 ± 4.1 times per month). Triptans were taken by 13 (25%) individuals 4.2 ± 3.4 times per month, and an opioid drug was taken by one. Altogether, 39 migraineurs were using acute migraine drugs 5.1 ± 4.4 times per month. Only two migraineurs were on drugs for the prophylaxis of migraine (propranolol). The demographic and clinical characteristics of the study participants are shown in Table 1. The migraineurs recruited at the Department of Medical Psychology and Sociology did not differ from those recruited through the email announcement with respect to demographic or clinical data (all p > 0.1).

Table 1.

Clinical and TCS findings in migraineurs and healthy control subjects.

		Migraine	Controls	p
Number		51	32
Gender	(number) M/F	11/40	8/24	0.72¹
Age	(mean ± SD) (Y)	29.7 ± 12.0	34.4 ± 13.0	0.10²
Age range	(Y)	19–70	22–71
DD	(mean ± SD) (Y)	15.9 ± 11.7	–
DD range	(Y)	2–53	–
Aura	(number)	34 (67%)	–
TTH	(number) n = 48	27 (56%)	–
MIDAS	(mean ± SD) n = 46	23.3 ± 36.2	–
HDs/3 months	(mean ± SD) n = 46	14.4 ± 13.4	–
VAS	(mean ± SD) n = 46	6.5 ± 1.8	–
BDI	(mean ± SD) n = 46	9.5 ± 8.5	–
Allodynia	(mean ± SD) n = 46	2.0 ± 2.1	–
SN	(mean ± SD) (cm²)	0.18 ± 0.08	0.18 ± 0.09	0.79³
MBR ↓	(number)	27 (53%)	6 (19%)	0.002 ¹
RN ↕	(number)	3 (6%)	0 (0%)	0.42¹
CN ↑	(number)	4 (8%)	5 (16%)	0.27¹
LN ↑	(number)	3 (6%)	6 (19%)	0.07¹
3 V	(mean ± SD) (mm)	1.9 ± 1.8	2.2 ± 1.6	0.49²
LV	(mean ± SD) (mm)	11.3 ± 2.6	11.9 ± 1.9	0.30²

p: significance (significant values in bold).

chi-square test. ²t-test. ³Mann-Whitney U test.

CN ↑ denotes increased echogenicity of the caudate nucleus; DA, digitized image analysis; DD, disease duration; HDs, headache days; LN ↑, increased echogenicity of the lenticular nucleus; LV, width of the frontal horn of the lateral ventricle; MBR ↓, reduced echogenicity of the midbrain raphe; MIDAS, Migraine Disability Assessment Score; RN ↕, abnormal (reduced or increased) echogenicity of the red nucleus; SN, the substantia nigra; TTH, tension-type headache; VAS, pain severity on the visual analogue scale; and 3 V, width of third ventricle.

Transcranial sonography findings

Images of normal and hypoechogenic MBR are shown in Figure 1. The visual MBR echogenicity ratings correlated well with the echo intensity score in the digitized image analysis (Spearman test, r = 0.54, p < 0.001; see also Figure 1S in the supplementary material). Twenty-seven (53%) migraineurs showed a hypoechogenic MBR (mean visual grade 2.31 ± 0.74), but only six (19%) control subjects did (2.76 ± 0.55; odds ratio (OR) for diagnosis of migraine: 4.87, 95% CI, 1.72–13.8; χ² test, p = 0.002; Figure 2). The TCS findings are summarized in Table 1. The migraineurs recruited at the Department of Medical Psychology and Sociology did not differ from those recruited through the email announcement with respect to the TCS findings (all p > 0.1). Of the two participants with chronic migraine, one had a normal, and the other one a hypoechogenic MBR; the other TCS findings were unremarkable.

Figure 1.

Transcranial sonography (TCS) images of normal and reduced echogenicity of the midbrain raphe (MBR). The midbrain is encircled for better visualization (small circles: red nuclei). (a) TCS image of normal MBR. The MBR is clearly visible thanks to its high echogenicity (grade 3; arrow). (b) TCS image of MBR with moderately reduced echogenicity (grade 2; arrow). (c) TCS image of MBR with markedly reduced echogenicity (grade 1; arrow). The MBR is not visible despite the clear visibility of the red nuclei and basal cisterns. (d) MRI plane corresponding to the TCS images shown in (a), (b) and (c).

Figure 2.

Distribution of different grades of midbrain raphe echogenicity in migraineurs and control subjects. *χ² test, p = 0.006.

Relationship between TCS and clinical findings

The relation between the MBR echogenicity and the clinical characteristics of the migraineurs is shown in Table 2. The widths of the third ventricle were larger in the subjects with migraine with aura compared to those without aura (see also Table 1S in the supplementary material). The third-ventricle widths in the migraineurs with and without aura did not differ from the controls if controlled for age. There was no association between the duration of the migraine disorder and the TCS findings. The other clinical data, including the frequency and severity of migraine assessed on the visual analogue scale, were unrelated to the TCS findings. Migraineurs with a BDI score >11 did not differ from those with a score <12 with respect to visual or digitized measures of MBR echogenicity. These findings remained unchanged if the two chronic migraineurs were excluded from analysis.

Table 2.

Clinical data in migraineurs with normal or reduced echo signal of the midbrain raphe.

		Raphe echogenicity
		Normal	Reduced	p
Number		24	27
Gender	(number) M / F	7 / 17	4 / 23	0.21¹
Aura	(number)	16 (67%)	18 (67%)	1.0¹
TTH	(number)	12 (50%)	15 (55%)	0.83¹
Age	(mean ± SD) (Y)	30.0 ± 11.9	29.4 ± 12.2	0.88²
Age at onset	(mean ± SD) (Y)	12.2 ± 5.3	15.3 ± 10.5	0.19²
DD	(mean ± SD) (Y)	18.0 ± 12.7	14.2 ± 10.7	0.27²
MIDAS	(mean ± SD)	28.8 ± 47.9	17.3 ± 14.5	0.27³
VAS	(mean ± SD)	6.5 ± 1.3	6.7 ± 2.1	0.44³
HDs / 3 months	(mean ± SD)	12.8 ± 12.4	15.8 ± 14.4	0.19³
Allodynia	(mean ± SD)	1.7 ± 1.9	2.2 ± 2.3	0.38³
BDI score	(mean ± SD)	9.7 ± 9.7	9.2 ± 7.5	0.74³
Non-opioid analgesics / month	(mean ± SD)	2.5 ± 2.2	5.8 ± 4.4	0.007 ³
Any analgesics / month	(mean ± SD)	3.6 ± 3.2	6.3 ± 4.9	0.036³
Triptans / month	(mean ± SD)	5.2 ± 4.3	3.4 ± 2.6	0.31³

p: significance (significant values p < 0.01 in bold; for details, see text).

chi-square test. ²t-test. ³Mann-Whitney U test.

DD denotes disease duration; HDs, headache days; BDI, Beck Depression Inventory; MIDAS, Migraine Disability Assessment Score; TTH, tension-type headache; and VAS, migraine pain severity on the visual analogue scale.

Relationship between TCS findings and self-medication

The migraineurs with hypoechogenic MBR had more days per month with use of non-opioid analgesics compared to those with normal echogenic MBR (Mann-Whitney U test, p = 0.007). A lower grade of MBR echogenicity correlated with both an increasing number of users (Spearman test, r = −0.32, p = 0.024; Figure 3) and the frequency of the intake of non-opioid analgesics (r = -0.45, p = 0.011). MBR echogenicity was unrelated to the number of triptan users (p = 0.96) and the frequency of triptan intake (p = 0.39). With the two chronic migraineurs excluded, all the results remained on the same level of significance.

Figure 3.

Percentage of patients taking analgesics (over-the-counter (OTC) analgesics and non-steroidal anti-inflammatory drugs (NSAIDs)) and triptans for acute pain relief according to ratings of the midbrain raphe echogenicity. Sums of more than 100% per group may be possible due to individuals taking both medications. Lower raphe echogenicity correlated with a higher number of users of analgesics (Spearman test, r = −0.32, p = 0.024) and a higher frequency of intake of analgesics (r = −0.45, p = 0.011; not shown). Raphe echogenicity was unrelated to the number of triptan users (p = 0.96) or the frequency of triptan intake (p = 0.39; not shown).

Relationship between TCS and neurophysiologic findings

The digitized measures of MBR echogenicity correlated with the amplitude of tCNV (r = 0.76, p = 0.028; see also Figure 2S in the supplementary material), but not iCNV, oCNV, or PINV (all p > 0.3). The other TCS findings were unrelated to CNV measures.

Discussion

The data obtained in this study show that a hypoechogenic MBR is a frequent TCS finding in migraineurs with or without aura compared to healthy controls. Lower MBR echogenicity in migraineurs is associated with higher use of analgesics, but not with use of triptans or with migraine frequency or severity. Compared to migraineurs without aura, those with aura have larger third-ventricle widths. Other TCS findings do not differ between diagnostic groups or subgroups. The potential limitations of this study include varying treatments, with some migraineurs taking multiple drugs, some staying on one drug, some receiving psychological therapy, and others being treatment naïve. The study heavily relied on interview data. To minimize the potential bias caused by the latter we applied only validated interviews. In addition, the recruitment of the majority of the migraineurs from a student population rather than from a head pain clinic may have caused a bias. In particular, the higher prevalence of aura in our cohort (67%) compared to larger populations of migraineurs (about 30%) could have contributed to the effects seen (17).

The frequency of MBR hypoechogenicity in our control group (19%) corresponds to the mean frequency of 15% seen in healthy subjects assessed in a recent meta-analysis (11). This rate clearly deviates from that in our migraine group (53%), which, however is lower than the rate in patients with depressive disorders (∼67%) (11). Our findings are in contrast to the previously reported equal prevalence of MBR hypoechogenicity in healthy subjects and migraineurs (18). This recent TCS study included a smaller sample of patients and applied only visual and not digitized image analysis. Still, this discrepancy may be due to the rigorous exclusion of migraineurs with a score of ≥11 on the BDI in the earlier study, while we only excluded subjects with a history of depressive disorder that involved medical consultation or treatment. At the mesencephalic level, the brainstem raphe contains the superior central nucleus and the dorsal raphe nucleus, which is responsible for the major part of the serotonergic innervation of the prefrontal cortex (19). Neuroimaging studies have revealed changes in this system in migraine patients, including altered 5-HT_1A receptor availability in the pontine raphe nucleus (20), and functional and structural alterations in the dorsal rostral brainstem in the region of the locus coeruleus, MBR and periaqueductal grey matter (5,6).

Reduced MBR echogenicity was reported earlier as a typical feature of depressive disorders (8 –11). As we excluded patients with a history of medically treated depression in our study, the true prevalence of reduced MBR echogenicity may be even higher in an unselected sample of migraineurs. What causes the change in MBR echogenicity on a histological level is currently a matter of debate. Preliminary post-mortem findings in individuals with depressive disorders have linked this alteration to a shift in tissue cell density and the disruption of fibre tracts passing the pontomesencephalic midline (9). It has been discussed that the reduced echo signal of the raphe reflects an alteration of the raphe nuclei rather than the fibre tracts in migraineurs (18).

As a correlate of the abnormal cortical information processing of sensory stimuli in migraineurs, often an altered CNV amplitude is observed, which seems to be an endophenotypic marker for migraine (3,4). While the iCNV is thought to indicate the level of expectancy mediated by the noradrenergic system, the tCNV rather reflects motor preparation and mobilization, and has been discussed as being related to the activity of the dopaminergic system (3,4,21). The differences in iCNV between migraineurs and controls are pronounced and highly significant (4). However, the functional meaning of tCNV is less clear. We found a correlation between lower MBR echogenicity and higher tCNV amplitude. A number of studies have demonstrated that the mesial wall motor areas (supplementary/cingulate motor areas) as well as the primary motor and sensory cortex participate in generating the tCNV (22). Serotonergic neurons within the rostral raphe complex of the mesencephalon and rostral pons (caudal linear, dorsal raphe and median raphe nuclei) project primarily to the forebrain (19). The findings of the present study link morphologic alteration of the MBR and tCNV, which might therefore reflect disturbance of the serotonergic rather than the dopaminergic system. However, one earlier TCS study on healthy subjects that compared MBR echogenicity and the loudness dependence of auditory evoked potentials, thought to be an indirect indicator of central serotonergic activity, failed to show a correlation between these two measures (23).

In another study of depressed patients, reduced MBR echogenicity was related to higher responsivity to serotonin reuptake inhibitors (10), also pointing towards an alteration of the serotonergic system. Interestingly, a lesion of the dorsal raphe nucleus induced supersensitivity to serotonin in isolated cerebral arteries in cats (24). Genetic studies on migraine showed an association of polymorphisms in the serotonin transporter (5-HTT) with migraine (25,26). It needs to be elucidated whether the subgroup of migraineurs with reduced MBR echogenicity might be characterized by genetic polymorphisms related to altered serotonin metabolism.

Another finding of the present study is that migraine patients with a hypoechogenic MBR take more non-opioid analgesics (paracetamol and NSAIDs) than patients with normal MBR echogenicity. It is generally accepted that these analgesics exert, in addition to cyclooxygenase inhibition, an effect on the central modulation and integration of noxious stimuli, with the exact mechanisms still remaining under discussion. The analgesic effect of NSAIDs is accomplished by the activation of descending, pain-inhibitory serotonergic pathways (27). Pharmacological blocking of serotonin receptors results in extensive or total loss of analgesic efficacy. Using a novel MRI technique that measures regional cerebral blood flow, not only could it be shown that the rostral ventromedial medulla, including the raphe nuclei, is involved in the perception of pain, but it could also be identified as a main site of analgesic interaction with ibuprofen (28).

Remarkably, the distribution of triptan users was equal across the groups with different ratings of MBR echogenicity. Triptans which act as 5-HT_1B/1D agonists are suggested to achieve their analgesic effect via disruption of the trigemino-cortical connectivity, thus explaining their analgesic effect being specific to headache pain (29). In the human brain, 5-HT_1B receptors are mainly expressed in the basal ganglia and in the frontal cortex, where they convey presynaptic inhibitory effects (30). 5-HT_1D receptors are expressed to a lesser extent, e.g. as auto receptors in the dorsal raphe nucleus. Our data do not show an association between the use of 5-HT_1B/1D agonists and echogenicity of the basal ganglia or the MBR. According to our findings, the effect of triptans appears to be less dependent on the state of the serotonergic MBR nuclei, which supports the idea of different targets for triptans versus classical analgesics. The missing relation between MBR echogenicity and triptan use is also supported by our finding that MBR echogenicity is unrelated to the frequency or severity of migraine pain. Taken together, our findings suggest that MBR echogenicity is associated with a change in the reaction to the headache rather than the intensity of the headache.

The TCS findings for other deep brain structures were unremarkable in the migraineurs. Abnormal hyperechogenicity of the substantia nigra, which is present in about 9% of the healthy population, indicates subclinical malfunction of the nigrostriatal dopaminergic system and has been identified as a risk factor for Parkinson’s disease (8,31). The results of a recent cohort study suggest a common vulnerability to, or common consequences of, migraine and late-life Parkinsonism (32). However, we did not detect an increased frequency of substantia nigra hyperechogenicity in migraineurs, which separates migraineurs from other risk groups for subsequent Parkinson’s disease (8). In our cohort, third-ventricle widths were larger in migraineurs experiencing aura symptoms compared to those without aura, but neither group differed from healthy subjects. A similar group difference has been reported recently which however failed statistical significance (18). Given the limited size of our study and the earlier study cohorts, this finding remains to be validated. It was proposed earlier that a cyst of the third ventricle causes migraine with aura (33). Volumetric changes of pain-related cortical areas as well as thalamic nuclei in migraine patients have been demonstrated, however, irrespective of association with aura symptoms (34,35). One voxel-based morphometry MRI study that compared migraine patients with aura to those without aura detected an increased density of the periaqueductal gray matter and of the dorsolateral pons in migraineurs experiencing aura (34). Further study is warranted to assess the changes of structures near the third ventricle that may be specific for migraine with aura.

Conclusions

Reduced MBR echogenicity is frequent in migraineurs with or without aura compared to healthy controls. This finding is likely to reflect an alteration of the serotonergic raphe nuclei and relates to higher use of non-opioid analgesics (NSAIDs and paracetamol), but not to use of triptans. MBR echogenicity is, however, unrelated to migraine severity. Compared to migraineurs without aura, those with aura have larger third-ventricle widths. The sonographic findings for the basal ganglia and substantia nigra are unremarkable in migraineurs.

Clinical implications

Midbrain raphe alteration is frequent in migraineurs and relates to self-medication behavior but not to frequency or severity of migraine.

Our findings support the idea that TCS might be useful to detect migraineurs with chronically altered serotonergic system.

Further studies will clarify the individual course of raphe echogenicity and its diagnostic value for the identification of individuals at risk of developing chronic headache in association with medication overuse.

Footnotes

Acknowledgement

The authors wish to thank Ms Elaine Reape for careful reading and critical discussion on the manuscript.

Declaration of conflicting interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: GH, PK, BM and AR report no competing interests. TPJ has served on advisory boards for Pharmallergan and received honoraria from Autonomic Technologies, Inc., Hormosan, MSD, Pfizer and Pharmallergan. UW received speaker honoraria and travel grants from Abbvie, Bayer Vital, Ipsen Pharma, Merz Pharmaceuticals and Pfizer.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

Hamel

. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27: 1293–1300.

Noseda

Burstein

. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain 2013; 154: S44–53.

Böcker

Timsit-Berthier

Schoenen

et al.

Contingent negative variation in migraine. Headache 1990; 30: 604–609.

Kropp

Wallasch

Müller

et al.

Disease duration of episodic migraine correlates with modified amplitudes and habituation of contingent negative variation. J Neural Transm (Vienna) 2015; 122: 877–885.

Bahra

Matharu

Buchel

et al.

Brainstem activation specific to migraine headache. Lancet 2001; 357: 1016–1017.

Weiller

May

Limmroth

et al.

Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658–660.

Kruit

Launer

Overbosch

et al.

Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia 2009; 29: 351–359.

Walter

Školoudík

. Transcranial sonography (TCS) of brain parenchyma in movement disorders: quality standards, diagnostic applications and novel technologies. Ultraschall Med 2014; 35: 322–331.

Becker

Berg

Lesch

et al.

Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. Int J Neuropsychopharmacol 2001; 4: 21–31.

10.

Walter

Prudente-Morrissey

Herpertz

et al.

Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Res 2007; 155: 67–73.

11.

Krogias

Walter

. Transcranial sonography findings in depression in association with psychiatric and neurologic diseases: a review. J Neuroimaging 2016; 26: 257–263.

12.

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629–808.

13.

Müller

Baum

Holzhausen

et al.

The Rostock Headache Questionnaire (‘Rokoko’) –validation of a tool to screen and to qualify primary headaches. Fortschr Neurol Psychiatr 2014; 82: 145–148.

14.

Lipton

Stewart

Sawyer

et al.

Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001; 41: 854–861.

15.

Beck

Ward

Mendelson

et al.

An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.

16.

Šilhán

Jelínková

Walter

et al.

Transcranial sonography of brainstem structures in panic disorder. Psychiatry Res 2015; 234: 137–143.

17.

Launer

Terwindt

Ferrari

. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999; 53: 537–542.

18.

Ayzenberg

Nastos

Strassburger-Krogias

et al.

Hypoechogenicity of brainstem raphe nuclei is associated with increased attack frequency in episodic migraine. Cephalalgia 2016; 36: 800–806.

19.

Hornung

. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003; 26: 331–343.

20.

Demarquay

Lothe

Royet

et al.

Brainstem changes in 5-HT1A receptor availability during migraine attack. Cephalalgia 2011; 31: 84–94.

21.

Nagel-Leiby

Welch

D'Andrea

et al.

Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia 1990; 10: 317–329.

22.

Cui

Egkher

Huter

et al.

High resolution spatiotemporal analysis of the contingent negative variation in simple or complex motor tasks and a non-motor task. Clin Neurophysiol 2000; 111: 1847–1859.

23.

Krogias

Fischer

Meves

et al.

Brainstem raphe alterations depicted by transcranial sonography do not result in serotonergic functional impairment. J Neuroimaging 2013; 23: 477–483.

24.

Moreno

Conde

la Luz Fraile de

et al.

Lesion of the dorsal raphe nucleus induces supersensitivity to serotonin in isolated cat middle cerebral artery. Brain Res 1991; 538: 324–328.

25.

Marziniak

Mössner

Schmitt

et al.

A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology 2005; 64: 157–159.

26.

Park

Han

Yang

et al.

Serotonin transporter protein polymorphism and harm avoidance personality in migraine without aura. Headache 2006; 46: 991–996.

27.

Miranda

Lemus

Pinardi

. Effect of the inhibition of serotonin biosynthesis on the antinociception induced by nonsteroidal anti-inflammatory drugs. Brain Res Bull 2003; 61: 417–425.

28.

Hodkinson

Khawaja

O’Daly

et al.

Cerebral analgesic response to nonsteroidal anti-inflammatory drug ibuprofen. Pain 2015; 156: 1301–1310.

29.

Kröger

May

. Triptan-induced disruption of trigemino-cortical connectivity. Neurology 2015; 84: 2124–2131.

30.

Pytliak

Vargová

Mechírová

et al.

Serotonin receptors – from molecular biology to clinical applications. Physiol Res 2011; 60: 15–25.

31.

Berg

Behnke

Seppi

et al.

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013; 28: 216–219.

32.

Scher

Ross

Sigurdsson

et al.

Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. Neurology 2014; 83: 1246–1252.

33.

Lane

Jenkins

van Dellen

et al.

Migraine with atypical visual aura caused by colloid cyst of the third ventricle. Cephalalgia 2010; 30: 996–999.

34.

Rocca

Ceccarelli

Falini

et al.

Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke 2006; 37: 1765–1770.

35.

Magon

May

Stankewitz

et al.

Morphological abnormalities of thalamic subnuclei in migraine: a multicenter MRI study at 3 tesla. J Neurosci 2015; 35: 13800–13806.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB